High-Dose Laquinimod Dropped Due to Cardiac Issues in MS High-Dose Laquinimod Dropped Due to Cardiac Issues in MS

Teva has discontinued development of the 1.2-mg and 1.5-mg doses because of eight cardiovascular events in two clinical trials. Investigation with the 0.6-mg dose continues. Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news